A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Actinic Keratosis
Interventions
DRUG

PEP005 (Ingenol Mebutate) gel, 0.015%

once daily for 3 consecutive days

DRUG

Vehicle Gel

once daily for 3 consecutive days

Trial Locations (21)

4152

South East Dermatology, Belmont Specialist Centre, Carina Heights

4217

The Skin Centre, Benowa

14623

Dermatology Associates of Rochester, PC, Rochester

24501

The Education and Research Foundation, Lynchburg

28207

Dermatology, Laser Vein Specialists of the Carolinas, Charlotte

32204

North Florida Dermatology Associates, PA, Jacksonville

46032

Laser Skin Surgery Center of Indiana, Carmel

46168

The Indiana Clinical Trials Center, PC, Plainfield

47713

Deaconess Clinic, Inc, Evansville

60005

Altman Dermatology Associates, Arlington Heights

71913

Burke Pharmaceutical Research, Hot Springs

77056

Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston

78229

Progressive Clinical Research, San Antonio

78759

DermResearch, Inc., Austin

87106

Academic Dermatology Associates, Albuquerque

89002

Karl G. Heine Dermatology, Henderson

94538

Center for Dermatology, Fremont

97223

Oregon Medical Research Center, PC, Portland

99204

Premier Clinical Research, Spokane

Unknown

Skin Specialists, PC, Omaha

10029-6574

Mount Sinai School of Medicine, New York

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Peplin

INDUSTRY

NCT00915551 - A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) | Biotech Hunter | Biotech Hunter